Sleep, Diabetic Retinopathy and Melatonin

Description

This study explores the use of melatonin in patients with diabetic retinopathy

Conditions

Diabetes Mellitus, Diabetic Retinopathy

Study Overview

Study Details

Study overview

This study explores the use of melatonin in patients with diabetic retinopathy

Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation

Sleep, Diabetic Retinopathy and Melatonin

Condition
Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Illinois at Chicago, Chicago, Illinois, United States, 60612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Type 2 diabetes (clinically diagnosed, taking anti-diabetes medications or history of elevated A1C≥6.5%)
  • * 40-65 years of age
  • * Diabetic retinopathy of at least moderate degree
  • * use of melatonin
  • * antidepressants or antipsychotics
  • * illicit drug use
  • * night shift work or travel beyond 2 time zones in the month before enrollment
  • * end stage renal disease requiring renal replacement therapy
  • * history of stroke or transient ischemic attacks
  • * history of dementia or memory impairment
  • * uncontrolled congestive heart failure or recent hospitalization for cardiac condition (6 months)
  • * chronic obstructive pulmonary disease requiring oxygen
  • * severe chronic liver disease such as cirrhosis
  • * ongoing treatment for major medical problems such as cancer
  • * history of severe hypoglycemia defined as hypoglycemic episodes requiring assistance from others within the past six months.
  • * Significant depressive symptoms
  • * untreated severe OSA (AHI≥ 30 events/hour),
  • * uncontrolled hypertension (blood pressure ≥ 160/100 mmHg),
  • * uncontrolled diabetes (A1C ≥ 11%),
  • * abnormal TSH
  • * abnormal liver function (AST or ALT\>3x upper limits of normal
  • * use of sedatives and hypnotics.
  • * clinically significant epiretinal membranes, clinically significant lens opacities, or cystoid macular edema, iris neovascularization, iris atrophy, or an asymmetrically shaped pupil, nuclear sclerotic, posterior subcapsular, or cortical lens opacities greater than 2+, a history of pan-retinal photocoagulation.
  • * hemoglobin \<11.5 g/dL in women and \<13.5 g/dL in men.

Ages Eligible for Study

40 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Illinois at Chicago,

Study Record Dates

2026-06